Trial Profile
A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary) ; Vinorelbine (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 10 Apr 2017 Planned primary completion date changed from 1 Oct 2021 to 1 Jul 2022.
- 10 Apr 2017 Status changed from not yet recruiting to recruiting.